A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It also provides clinical and technical support services, such as physician interpretation training, nurse and technologist training, billing and prior-authorization assistance, physician over-read services, 24/7 clinical and technical support, priority response with after-hours service availability, equipment uptime guarantees and software upgrades, and remote system diagnostics and maintenance capabilities. The company sells its products through internal sales and marketing team. It serves healthcare providers, imaging centers, hospitals, and cardiology practices. The company was incorporated in 1983 and is headquartered in North Tonawanda, New York.
Financial Summary
| Share Statistics | POSC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $54.5 | $405.9 | 16% |
|
| Shares Out (Mil) | 32.8 | 41.6 | 38% |
|
| Institutional Ownership | na | 83.1% | na |
|
| Float (Mil) | na | 35.6 | na |
|
| Beta | 0.20 | 0.88 | 13% |
|
| Avg Daily Volume (000s) | 17 | 337 | 20% |
|
| Price Change (52-week) |
(7.3%) | 65.0% | 41% |
|
| Growth | POSC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (29.1%) | 11.8% | 1% |
|
| Net Income (5yr) | (5.8%) | (5.9%) | 33% |
|
| EPS (5yr) | 32.9% | 10.2% | 83 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.0% | (15.6%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | POSC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $119 | 1% |
|
| Net Income (TTM) (Mil) | ($10) | ($9) | 29% |
|
| EPS (TTM) | ($0.314) | ($0.400) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($3) | 26% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 10% |
|
| Enterprise Value (Q1) (Mil) | $60 | $371 | 17% |
|
| Valuation | POSC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.04 | na |
|
| P/E | na | 27.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.6 | na |
|
| Ratios | POSC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (531.9%) | 58.5% | 0% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | na | (13.1%) | na |
|
| ROE | na | (13.1%) | na |
|
| Liabilities to Assets | 138.2% | 46.1% | 97% |
|
| F-Score | 1 | 4 | 1% |
|
Positron Corporation did not pass any screens on 9/1/2026.
